YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Samsung Faces Major Strike Threat as Union Restarts Pay Talks 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Applied Materials Forecasts Strong Q3 Revenue as AI Chip Demand Accelerates 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
SAN RAMON, Calif., Sept. 20, 2016 -- Galena Biopharma, Inc. (NASDAQ:GALE), a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the Sachs Associates 16th Annual Biotech in Europe Forum. The presentation will take place on Wednesday, September 28, 2016 at 10:15 a.m. local time at the Congress Center Basel in Basel, Switzerland.
The presentation will be webcast and available on the Investors section of the Company's website at http://investors.galenabiopharma.com/events.cfm.
About Galena Biopharma
Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of hematology and oncology therapeutics that address unmet medical needs. Galena’s pipeline consists of multiple mid-to-late-stage clinical assets led by its hematology asset, GALE-401, and novel cancer immunotherapy programs including NeuVax™ (nelipepimut-S) and GALE-301/GALE-302. For more information, visit www.galenabiopharma.com.
NeuVax is a trademark of Galena Biopharma, Inc.
Contact: Remy Bernarda SVP, Investor Relations & Corporate Communications (925) 498-7709 [email protected]
